breast tumor Articles
-
A novel h19 antisense RNA overexpressed in breast cancer contributes to paternal IGF2 expression
The H19/IGFf2 locus belongs to a large imprinted domain located on human chromosome 11p15.5 (homologue to mouse distal chromosome 7). The H19 gene is expressed from the maternal allele, while IGF2 is paternally expressed. Natural antisense transcripts and intergenic transcription have been involved in many aspects of eukaryotic gene expression, including genomic imprinting and RNA interference. ...
-
How 4D Path and PathPresenter aim to further AI-enabled digital pathology for breast tumor profiling
The digital pathology software company PathPresenter (Montville, New Jersey) and the precision oncology platform firm 4D Path have entered into a partnership that could improve the diagnostic accuracy of breast tumor profiling. PathPresenter has developed a digital workflow tool for clinicians, pathologists and pharma companies to aggregate medical data. ...
By 4D Path Inc.
-
Feedback regulation between zipcode binding protein 1 and β-catenin mrnas in breast cancer cells
ZBP1 (zipcode binding protein 1) is an RNA-binding protein involved in many posttranscriptional processes, such as RNA localization, RNA stability, and translational control. ZBP1 is abundantly expressed in embryonic development, but its expression is silenced in most adult tissues. Reactivation of the ZBP1 gene has been reported in various human tumors. In this study, we identified a detailed ...
-
Cyclin D1 Genetic Heterozygosity Regulates Colonic Epithelial Cell Differentiation and Tumor Number in ApcMin Mice
Constitutive ß-catenin/Tcf activity, the primary transforming events in colorectal carcinoma, occurs through induction of the Wnt pathway or APC gene mutations that cause familial adenomatous polyposis. Mice carrying Apc mutations in their germ line (ApcMin) develop intestinal adenomas. Here, the crossing of ApcMin with cyclin D1–/– mice reduced the intestinal tumor number in animals genetically ...
-
Global Partnership to Improve Diagnostic Accuracy of Breast Cancer
Femtech World featured our partnership with PathPresenter to distribute the 4D Q-plasia OncoReader Breast within PathPresenter’s ClinPx Clinical Workflow Platform in their magazine. The primary purpose of integrating 4D Path’s proprietary algorithms within the PathPresenter ClinPx platform is to potentially improve the throughput, reliability, and quality of consultations ...
By 4D Path Inc.
-
Phase lb study of venadaparib, a potent and selective PARP inhibitor, in homologous recombination repair (HRR) mutated breast cancer
Poly ADP-ribose polymerase (PARP) is an enzyme that is central to the repair of DNA replication errors and are currently approved for ovary, breast, pancreas and prostate cancers. VASTUS study (NCT04174716)1' is a basket trial investigating the safety and efficacy of venadaparib in 6 cohorts (active recruiting) of different tumors, including breast ...
-
Science: A protein-protein interaction map of breast cancer constructed
Advances in DNA sequencing technology have made it possible to extensively analyze the breast tumor genome and construct a catalog of gene mutations that may initiate or drive tumor progression. In addition to the well-known common mutations in oncogenes (such as TP53 and PIK3CA), breast cancer also contains a variety of rare mutations that have a low incidence in the patient population. Despite ...
-
Abstract A106: Development of IDX-1197, a novel, selective, and highly potent PARP inhibitor
Abstract Background: PARP inhibitors have demonstrated clinically meaningful increase in progression-free survival as a single agent in women with recurrent ovarian cancer following a response to platinum-based chemotherapy. However, there still needs more improvement in efficacy because PARP inhibitors have comparatively low efficacy in non-germline BRCA-mutated patients. We aimed to develop ...
-
CD Genomics Perspective: The Application of RNA-Seq and DNA-Seq in Cancer Research
Clinicians can make better diagnostic and treatment decisions using the data obtained by next-generation sequencing (NGS) technologies. Breast cancers, for example, have typically been diagnosed using mammography, physical exam, and histology. Genetics became more significant after the discoveries of oncogenes and other biomarkers. Today, commercially available microarray-based tests enable more ...
By CD Genomics
-
ADC Drugs For Breast Cancer Treatment
Breast cancer is the malignant tumor with the highest morbidity and mortality among women worldwide. At present, the main therapeutic methods include surgery, chemotherapy, radiotherapy, endocrine therapy and targeted therapy, etc. The development and marketing of new drugs have far-reaching significance in improving the survival of breast cancer patients and changing the pattern of breast cancer ...
-
Novel Tumor Bed Marking in Breast Cancer: Expanding Beyond Lumpectomy
VeraForm® placement to assist with localization and delivery of adjuvant radiation Historically, lumpectomies resulted in a scar immediately over the lumpectomy site, dictating delivery of adjuvant radiation on scar location, and frequently on the presence of a seroma. Currently, the question persists as to the optimal means to help direct the radiation oncologist to effectively deliver ...
-
Early Detection Saves Lives KBCT Can Help
Despite breast cancer being the second most common cancer for women in the US, progress in the breast imaging space has been stagnant over the last few decades. This is evident in the countless women who are still misdiagnosed – either receiving a false positive or getting diagnosed in the later stages of the disease. Why Early Detection is Important According to the National Breast ...
-
Mapk4 May Be a New Target for the Treatment of Triple-Negative Breast Cancer
There is now growing evidence that the MAPK4 enzyme may be involved in cancer growth and resistance to specific therapies. Recently, an article titled " MAPK4 promotes triple negative breast cancer growth and reduces tumor sensitivity to PI3K blockade" was published in Nature Communications. By analyzing public genome databases, the researchers found that a large number of triple-negative ...
-
Antibody-Drug Conjugates For The Treatment of Prostate Cancer
Currently, ADC has played a significant role in the treatment of some malignant tumors, such as trastuzumab in the treatment of breast cancer, but its application in the treatment of prostate cancer (PCa) progress slowly. In recent years, ADC has made rapid progress in the treatment of metastatic castration-resistant prostate cancer (mCRPC). STEAP1, TROP2, PSMA, CD46, and B7-H3 are currently ...
-
What are the Possibilities for ADCs Targeting Trop2?
Antibody drug conjugate (ADC) research involves more and more targets, such as HER-2, Trop-2, Claudin-18.2, B7-H3 and B7-H4, etc. Trop-2 is a transmembrane glycoprotein. Its high expression is associated with the occurrence of many tumors and poor prognosis. It is a very popular ADC research target, second only to HER2. Currently, only Gilead's Trop-2 ADC drug Trodelvy has been approved for ...
By BOC Sciences
-
Autoimmune Diseases Targets
Thymic Stromal Lymphopoietin (TSLP) is a multifunctional cytokine that acts on various cell types, including dendritic cells, T cells, B cells, neutrophils, mast cells, eosinophils, and innate lymphoid cells, affecting their maturation, survival, and recruitment. It is well-known for its role in promoting type 2 immune responses, such as allergic diseases. In 2021, a monoclonal antibody targeting ...
-
The Role of MMP-3: Insights into Disease Progression and Therapeutic Potential
The MMP Family Matrix metalloproteinases (MMPs) are a family of enzymes belonging to the metzincin superfamily. There are 23 different types of secreted or membrane-anchored endopeptidases in the human body. MMPs are capable of degrading ECM proteins such as collagen, gelatin, laminin, fibronectin, fibrinogen, elastin, and proteoglycans. They were once considered regulators of the extracellular ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you